You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

intermediate-1 risk myelodysplastic syndromes

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anemia, MDS, Chronic Myelomonocytic Leukemia Trial in France, United States (Sotatercept)

Completed
Has Results
  • Anemia
  • +5 more
  • Denver, Colorado
  • +19 more
Oct 20, 2022

MDS Trial in Worldwide (Talacotuzumab, Daratumumab)

Completed
Has Results
  • Myelodysplastic Syndromes
  • Saint Louis, Missouri
  • +20 more
Dec 28, 2022

MDS, MDS, Thrombocytopenia Trial (Placebo, Romiplostim)

Completed
Has Results
  • MDS
  • +2 more
  • Placebo
  • Romiplostim
  • (no location specified)
Nov 4, 2022

MDS Trial in Dresden (ACE-536)

Completed
  • Myelodysplastic Syndromes
  • Dresden, Germany
    Acceleron Investigative Site
Apr 29, 2021

Anemia Trial in Dresden (ACE-536)

Completed
  • Anemia
  • Dresden, Germany
    Acceleron Investigative Site
Apr 29, 2021

Anemia in MDS Trial in Plantation, Bronx, Austin (TP-0184)

Completed
  • Anemia in Myelodysplastic Syndromes
  • Plantation, Florida
  • +2 more
Apr 4, 2022

High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,

Active, not recruiting
Has Results
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

MDS Trial in Bronx (Pyrimethamine)

Withdrawn
  • Myelodysplastic Syndromes
  • Bronx, New York
    Montefiore Medical Center
Sep 15, 2021

Myelodysplastic Syndrome (MDS) Trial in United States (AMV564 14-Day CIV)

Completed
  • Myelodysplastic Syndrome (MDS)
  • AMV564 14-Day CIV
  • Duarte, California
  • +4 more
Oct 11, 2021

Myelodysplastic Syndrome Trial in New York (Revlimid (Lenalidomide))

Active, not recruiting
Has Results
  • Myelodysplastic Syndrome
  • Revlimid (Lenalidomide)
  • New York, New York
    Columbia University Medical Center
Jan 12, 2022

MDS Trial in Chicago (Lenalidomide and azacitidine combination)

Terminated
Has Results
  • MDS
  • Lenalidomide and azacitidine combination
  • Chicago, Illinois
    Rush University Medical Center
Nov 2, 2020

MDS Trial (Decitabine/Cedazuridine, Magrolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • (no location specified)
Apr 18, 2023

MDS Trial in Germany, United States (Best Supportive Care, BI 836858)

Terminated
Has Results
  • Myelodysplastic Syndromes
  • Best Supportive Care
  • BI 836858
  • Jacksonville, Florida
  • +4 more
Dec 18, 2020

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)

Recruiting
  • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
  • Ocala, Florida
  • +3 more
Jan 30, 2023

MDS Trial in Worldwide (MBG453, Placebo, Hypomethylating agents)

Active, not recruiting
  • Myelodysplastic Syndromes
  • Duarte, California
  • +46 more
Jan 20, 2023

MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

Not yet recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Subcutaneous azacitidine
  • Oral decitabine/cedazuridine
  • Newcastle, New South Wales, Australia
    Calvary Mater Newcastle
May 29, 2023

MDS Trial (Imetelstat)

Available
  • Myelodysplastic Syndromes
  • (no location specified)
Jun 30, 2023

REVLIMID® Treatment of IPSS Low- or Intermediate-1-risk

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Anyang, Korea, Republic of
  • +12 more
Apr 6, 2021

MDS Trial in United States (ARRY-614, p38/Tie2 inhibitor; oral)

Completed
  • Myelodysplastic Syndromes
  • ARRY-614, p38/Tie2 inhibitor; oral
  • Tampa, Florida
  • +3 more
Sep 4, 2020

Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Houston (Anti-Thymocyte Globulin,

Recruiting
  • Aplastic Anemia
  • +3 more
  • Anti-Thymocyte Globulin
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 1, 2021

Anemia Trial (Luspatercept)

Not yet recruiting
  • Anemia
  • Luspatercept
  • (no location specified)
May 26, 2023

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +5 more
  • Canakinumab
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

MDS Trial in Miami, New York (50 gm CIVI/24 hours x 5 days every 4 week)

Recruiting
  • Myelodysplastic Syndromes
  • 50 gm CIVI/24 hours x 5 days every 4 week
  • Miami, Florida
  • +1 more
Jul 6, 2022

MDS Trial in Worldwide (Oral Azacitidine, Placebo for Oral Azacitidine)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Oral Azacitidine
  • Placebo for Oral Azacitidine
  • Buenos Aires, Argentina
  • +1 more
Aug 1, 2022

Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Chicago (Laboratory Biomarker

Completed
  • Acute Myeloid Leukemia
  • +4 more
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
May 12, 2021